Mereo Biopharma Group Plc
Research Mereo Biopharma Group Plc (MREO) on Bullrun: market cap USD 45.01M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMREO
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 45.01M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 6.72M
- Free cash flow-USD 4.61M
Valuation Snapshot
latest market cap is USD 45.01M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 500.00K | USD 41.88M | -USD 30.99M | n/a | -0.05 | USD 40.99M | USD 202.00K | USD 40.92M |
| FY2024 | USD 0 | USD 43.25M | -USD 32.83M | n/a | -0.06 | USD 69.80M | USD 6.43M | USD 60.97M |
| FY2023 | USD 10.00M | USD 29.47M | -USD 21.13M | 74.3% | -0.04 | USD 57.42M | USD 5.95M | USD 50.54M |
| FY2022 | USD 0 | -USD 42.22M | -USD 48.83M | n/a | -0.07 | USD 68.18M | USD 15.37M | USD 51.40M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 45.01M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 66.78M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 543.01M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 323.50M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 93.58M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 186.82M | n/a | n/a | n/a |
About Mereo Biopharma Group Plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Mereo Biopharma Group Plc's market cap?
Mereo Biopharma Group Plc's market capitalization is USD 45.01M.
What does Mereo Biopharma Group Plc do?
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.